TSLA
Tesla
-- 421.060 NVDA
NVIDIA
-- 134.700 PLTR
Palantir
-- 80.550 RGTI
Rigetti Computing
-- 9.3700 AMD
Advanced Micro Devices
-- 119.210 
NEWS
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
Turnstone Biologics Corp. (Nasdaq: TSBX) reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer (MSS mCRC). Key findings include:
- 25% overall response rate (ORR) and 50% disease control rate (DCR) among four evaluable patients
- One patient achieved a deep and durable ongoing complete response (CR)
- 50% of patients showed sustained clinical benefit, with notable progression-free survival
- TIDAL-01 demonstrated high titer, polyclonal, and multi-epitope tumor neoantigen-reactive T cells
- Generally well-tolerated safety profile
- 80% manufacturing success rate for TIDAL-01 in CRC
These results suggest TIDAL-01's potential to transform treatment for metastatic CRC and other solid tumors.
- 25% overall response rate (ORR) and 50% disease control rate (DCR) among four evaluable patients
- One patient achieved a deep and durable ongoing complete response (CR)
- 50% of patients showed sustained clinical benefit, with notable progression-free survival
- TIDAL-01 demonstrated high titer, polyclonal, and multi-epitope tumor neoantigen-reactive T cells
- Generally well-tolerated safety profile
- 80% manufacturing success rate for TIDAL-01 in CRC
These results suggest TIDAL-01's potential to transform treatment for metastatic CRC and other solid tumors.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment